Harmony Biosciences Holdings, Inc. (HRMY)
Stock Price:
$30.96 USD
-2.64 (-7.86%)
Updated Sep 21, 2020 4:00 PM EDT - Market closed
After-hours: $30.99 +0.03 (0.10%) Sep 21, 4:07 PM
Key Info
| Market Cap |
1.97B |
| Revenue (ttm) |
63.84M |
| Net Income (ttm) |
-106.99M |
| Shares Out |
63.68M |
| EPS (ttm) |
-2.33 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 21, 2020 |
| Last Price |
$30.96 |
| Previous Close |
$33.60 |
| Change ($) |
-2.64 |
| Change (%) |
-7.86% |
| Day's Open |
33.00 |
| Day's Range |
30.87 - 34.24 |
| Day's Volume |
260,020 |
| 52-Week Range |
30.87 - 47.37 |
More Stats
| Market Cap |
1.97B |
| Enterprise Value |
2.09B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
63.68M |
| Float |
20.85M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-2.33 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
347,261 |
| Short Ratio |
0.51 |
| Short % of Float |
1.98% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
30.88 |
| PB Ratio |
n/a |
| Revenue |
63.84M |
| Operating Income |
n/a |
| Net Income |
-106.99M |
| Free Cash Flow |
n/a |
| Net Cash |
-116.24M |
| Net Cash / Share |
-1.83 |
| Gross Margin |
6.92% |
| Operating Margin |
n/a |
| Profit Margin |
-229.45% |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$51.67*
(66.89% upside)
Low
43.0
Current: $30.96
High
61.0
Target: 51.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 6.00 | - |
| Gross Profit | 4.42 | - |
| Operating Income | -146 | -41.44 |
| Net Income | -152 | -39.90 |
| Shares Outstanding | 7.78 | 8.86 |
| Earnings Per Share | -24.07 | -7.91 |
| Operating Cash Flow | -75.44 | -38.80 |
| Capital Expenditures | -0.15 | -1.34 |
| Free Cash Flow | -75.59 | -40.14 |
| Cash & Equivalents | 24.46 | 83.52 |
| Total Debt | 97.95 | - |
| Net Cash / Debt | -73.49 | 83.52 |
| Assets | 107 | 89.28 |
| Liabilities | 118 | 7.75 |
| Book Value | -423 | -243 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Harmony Biosciences Holdings, Inc. |
| Country |
United States |
| Employees |
150 |
| CEO |
John C.s Jacobs |
Stock Information
| Ticker Symbol |
HRMY |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: HRMY |
| IPO Date |
August 19, 2020 |
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.